| Acquired by | Teleflex |
| Price | $30M |
| Date | 6/12 |
| Website | semprusbio.com |
| @SemprusBio | |
| Category | BioTech |
| Phone | 617-577-7755 |
| info@semprusbio.com | |
| Employees | 27 |
| Founded | 2006 |
| Description | biotech functional medical surfaces |
| TOTAL | $27M |
| FUNDING TOTAL | $27M |
| Series A, 12/08 5AM Ventures Panagea Ventures | $8M |
| Series B, 12/10 SR One GlaxoSmithKline Foundation Medical Partners 5AM Ventures Pangaea Ventures | $18M |
| Grant, 10/11 | $1M |
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. Our innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Our current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.
